Anavex恢复符合纳斯达克定期报告要求

----- e7909_8-k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 2, 2026
ANAVEX LI
FE
SCIENCES CORP.
(Exact
name of Registrant as Specified in Its Charter)
Nevada
001-37606
98-0608404
(State
or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
630
5th Avenue
,
20th Floor
New
York
,
NY
USA
10111
(Address
of Principal Executive Offices)
(Zip
Code)
Registrant’s
Telephone Number, Including Area Code: 1-
844
-
689-3939
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $0.001 per share
AVXL
Nasdaq
Stock Market LLC
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
As previously disclosed, on May 20, 2026, Anavex Life
Sciences Corp. (“Anavex” or the “Company”) received a delinquency notification letter from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely
file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, the Company was not in compliance with Nasdaq Listing
Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange
Commission (“SEC”). On July 20, 2026, the Company timely submitted its plan to Nasdaq to regain compliance with Nasdaq Listing
Rule 5250(c)(1). On August 28, 2026, the Company filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026,
and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, with the SEC.
On September 2, 2026, the Company issued a press release
(the “Press Release”) announcing that the Company has received confirmation from Nasdaq that the Company has regained compliance
with Nasdaq Listing Rule 5250(c)(1).
A copy of the Press Release is attached as Exhibit
99.1 to this Current Report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated September 2, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANAVEX LIFE SCIENCES CORP.
Date: September 2, 2026
By:
/s/ Sandra Boenisch
Sandra Boenisch, CPA, CGA
Principal Financial Officer, Treasurer

----- e7909_ex99-1.htm -----
EX-99.1
2
e7909_ex99-1.htm
EXHIBIT 99.1
EXHIBIT 99.1
Anavex
Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex
Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all
Three Core Indications Forward
NEW YORK, NY, September 2,
2026
- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical
company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs,
today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained
compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the
Securities and Exchange Commission (“SEC”).
On August 28, 2026, the Company
filed its outstanding Form 10-Q filings for the second and third fiscal quarters of 2026 with the SEC. The Company is now in compliance
with all Nasdaq listing standards, and its common stock will continue to trade on the Nasdaq Global Select Market under the ticker “AVXL.”
About Anavex Life Sciences
Corp.
Anavex Life Sciences
Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for
the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at
www.anavex.com
.
Forward-Looking Statements
Statements in this press release
that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements
relating to the Company’s ability to continue trading on the Nasdaq Global Select Market. These statements are based on current
information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those
projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s
ability to maintain compliance with the Nasdaq Listing Rules; and other risks and uncertainties set forth in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”)
on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the
SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28,
2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s
Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings
and furnishings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences
Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except
as required by law.
Investor Relations & Media
Contact:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com
Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com
Company Contact:
Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email:
ir@anavexcorp.com